Reckitt Benckiser Group (OTCMKTS:RBGLY) Raised to Strong-Buy at Citigroup

Citigroup upgraded shares of Reckitt Benckiser Group (OTCMKTS:RBGLY - Free Report) to a strong-buy rating in a research report released on Tuesday, Zacks.com reports.

RBGLY has been the subject of several other reports. JPMorgan Chase & Co. lowered Reckitt Benckiser Group from an overweight rating to a neutral rating in a research report on Thursday, August 29th. UBS Group upgraded Reckitt Benckiser Group to a strong-buy rating in a research note on Wednesday, September 18th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of Hold.

Reckitt Benckiser Group Price Performance

Shares of RBGLY traded down $0.17 on Tuesday, hitting $12.06. The company's stock had a trading volume of 179,650 shares, compared to its average volume of 849,401. The firm's fifty day moving average price is $11.55 and its 200-day moving average price is $11.30. Reckitt Benckiser Group has a fifty-two week low of $10.24 and a fifty-two week high of $15.03.

Reckitt Benckiser Group Cuts Dividend

The firm also recently disclosed a dividend, which was paid on Monday, September 23rd. Investors of record on Monday, August 5th were paid a $0.1915 dividend. The ex-dividend date was Monday, August 5th.

About Reckitt Benckiser Group

Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.